Skip to main content
Caplight Logo









PerturbAI

PerturbAI

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://perturb.ai

Last Round

Pre Seed

Sep 1, 2025

Company Overview

PerturbAI operates in Healthcare & Life Sciences and is based in San Francisco, California. Its latest recorded funding round was a Pre Seed round in September 2025.

PerturbAI is a biotechnology company that develops an AI-enabled drug discovery platform by combining large-scale in vivo CRISPR perturbation with artificial intelligence to map causal biological relationships.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Foundation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

PerturbAI Comparables

Compare PerturbAI with similar companies based on industry and business-model similarity.

PerturbAI comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Synlico Inc.
87%
Algen Biotechnologies
84%
Myllia Biotechnology
84%
Book a demo to see all comparables

For institutional investors. Book with your work email.

PerturbAI Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Pre SeedSep 1, 2025
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Grace Zheng

Chief Executive Officer & Co-Founder

Founding Team

Caroline Moon

Consulting COO

Executive Team

For institutional investors. Book with your work email.

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 1, 2025

    Completed a Pre Seed funding round.

Book a demo to see all signals

For institutional investors. Book with your work email.

Recent news

Latest coverage and updates

  • partners_withOct 21, 2026

    In California on Oct 21st '26, PerturbAI and OpenAI, Inc. report a year-long collaboration that jointly develops AI reasoning agents to help scientists interpret complex biological data for drug discovery.

  • is_developingOct 21, 2026

    Perturb and OpenAI have jointly developed AI reasoning agents that analyze cellular responses, search scientific literature, and connect experimental results with biological knowledge to help scientists interpret complex data for drug discovery.

  • launchesOct 21, 2026

    PerturbAI unveils first-of-its-kind AI reasoning agents with OpenAI in California on Oct 21st '26 to help scientists interpret experimental data, connect findings with scientific literature, and identify testable biomedical hypotheses.

  • launchesOct 21, 2026

    PerturbAI unveils its drug discovery engine in Mar '26 to map genomic cause and effect in living organisms and generate prioritized drug targets.

  • partners_withOct 20, 2026

    PerturbAI, Scripps Research Translational Institute, and OpenAI collaborate to deploy thousands of AI agents that analyze millions of mouse brain cells and identify promising research leads related to brain diseases.

Book a demo to see all news

For institutional investors. Book with your work email.

PerturbAI Filings

Explore SEC and related filing metadata, where available.

PerturbAI filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about PerturbAI's valuation, stock price, and market status.

Is PerturbAI a public or private company?

PerturbAI is a private company.

What is the current stock price of PerturbAI?

PerturbAI is a private company, so its shares have no public market price. Caplight tracks PerturbAI's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is PerturbAI worth (valuation)?

Valuation information for PerturbAI is not publicly available.

Can I buy PerturbAI stock?

PerturbAI shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was PerturbAI's last funding round?

PerturbAI's most recent funding round was Pre Seed on September 1, 2025.

Who are the main investors in PerturbAI?

Investor information for PerturbAI is not publicly disclosed.

Will PerturbAI IPO soon?

No public IPO plans have been announced for PerturbAI.

How can I track PerturbAI secondary market activity?

Caplight tracks bids, offers, and trades in PerturbAI's shares on secondary markets.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range4
Year Founded2025
Last FundingSep 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?